Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016

Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016
Published Jul 13, 2016
65 pages — Published Jul 13, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016, provides in depth analysis on Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2)
- The report reviews Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create

  
Source:
Document ID
GMDHC0388TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Overview71
Therapeutics Development84
  Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Stage of Development81
  Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Therapy Area91
  Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Indication102
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Companies142
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Products under Development by Universities/Institutes162
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Therapeutics Assessment187
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action192
  Assessment by Route of Administration212
  Assessment by Molecule Type232
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Companies Involved in Therapeutics Development254
  Cleveland BioLabs, Inc.251
  Neuropore Therapies, Inc.261
  Opsona Therapeutics Limited271
  Vascular Biogenics Ltd.281
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Drug Profiles2922
  CBLB-612 Drug Profile292
  CBLB-613 Drug Profile311
  DMT-200 Drug Profile322
  DMT-210 Drug Profile341
  DMT-220 Drug Profile351
  infectious vaccine Drug Profile361
  OPN-305 Drug Profile372
  P-13 Drug Profile391
  P-MAPA Drug Profile402
  Small Molecules to Agonize TLR2 for Neurodegenerative Diseases Drug Profile421
  Small Molecules to Antagonize TLR-1 and TLR-2 for Infectious Disease and Neuroinflammation Drug Profile431
  Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases Drug Profile441
  SP-16 Drug Profile451
  Synthetic Peptide to Target PPAR-Gamma and TLR-2 and IBD and Tissue Injury Drug Profile461
  Vaccine to Target MUC-1 and TLR-2 for Breast Cancer Drug Profile471
  VB-201 Drug Profile483
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Dormant Projects513
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Discontinued Products541
Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) Featured News &Press Releases559
  May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study551
  Jan 26, 2016: Cleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation551
  Jul 13, 2015: Cleveland BioLabs Announces Results of Phase 1 Study of CBLB612 in Russian Federation561
  Apr 02, 2015: Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612561
  Mar 16, 2015: Cleveland BioLabs Announces Completion of Dosing in Phase 1 Study of CBLB612 in Russian Federation571
  Mar 02, 2015: Opsona Therapeutics commences Part B of phase II study of Blocking Toll-Like Receptor 2 in Extended Criteria Donor renal transplant recipients at high risk of Early Graft Dysfunction571
  Feb 23, 2015: Opsona Therapeutics Patent issued in USA covering an antibody directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof571
  Feb 18, 2015: Opsona Therapeutics Patent issued in US and EU covering the Opsona-developed antibody OPN-305, which is directed against Toll-like Receptor-2 (TLR-2) and the use and development thereof581
  Feb 17, 2015: VBL Therapeutics Reports Topline Results From Phase 2 Studies of VB-201 in Psoriasis and Ulcerative Colitis591
  Feb 09, 2015: VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease601
  Feb 06, 2015: VBL Therapeutics Receives European Patent Issuance on Lecinoxoid Platform Technology611
  Jan 29, 2015: VBL Therapeutic In Cooperation With KCR Reported LPO In Phase 2 Of VB-201611
  Jan 27, 2015: Opsona Therapeutics initiates phase I / II prospective open in patients with myelodysplastic syndrome second line of lower level (low and intermediate-1) with OPN-305 label ...621
  Jan 27, 2015: Opsona Therapeutics OPN-305 examines pretreatment myelodysplasia621
  Jan 26, 2015: Opsona Therapeutics initiates a prospective open label Phase I/II study in second-line lower (Low and intermediate-1) risk myelodysplastic syndrome (MDS) with OPN-305, a First-in Class Monoclonal622
Appendix642
  Methodology641
  Coverage641
  Secondary Research641
  Primary Research641
  Expert Panel Validation641
  Contact Us641
  Disclaimer651

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-2-Toll-Interleukin-1-Receptor-Like-Protein-4-or-CD282-or-TLR2-Pipeline-Review-H2-2016-2088-16195>
  
APA:
Global Markets Direct - Market Research. (2016). Toll Like Receptor 2 (Toll/Interleukin 1 Receptor Like Protein 4 or CD282 or TLR2) - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-2-Toll-Interleukin-1-Receptor-Like-Protein-4-or-CD282-or-TLR2-Pipeline-Review-H2-2016-2088-16195>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.